Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 15 new employees hired in October 2024. The awards, consisting of 12,165 restricted stock units (RSUs), were approved by the Compensation Committee under the company's 2024 Employment Commencement Incentive Plan. The RSUs will vest over four years, with one-fourth vesting annually on the grant date anniversary. Sarepta, a leader in precision genetic medicine for rare diseases, maintains leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies, with over 40 programs in development.
Sarepta Therapeutics (NASDAQ:SRPT) ha concessto premi azionari a 15 nuovi dipendenti assunti nell'ottobre del 2024. I premi, costituiti da 12.165 unità azionarie vincolate (RSU), sono stati approvati dalla Commissione Compensazioni nell'ambito del Piano Incentivi per l'Inizio Occupazione 2024 della società. Le RSU matureranno in quattro anni, con un quarto che matura annualmente all'anniversario della data di concessione. Sarepta, leader nella medicina genetica di precisione per le malattie rare, mantiene posizioni di leadership nella distrofia muscolare di Duchenne e nelle distrofie muscolari a cintura, con oltre 40 programmi in sviluppo.
Sarepta Therapeutics (NASDAQ:SRPT) ha otorgado premios en acciones a 15 nuevos empleados contratados en octubre de 2024. Los premios, que consisten en 12,165 unidades de acciones restringidas (RSUs), fueron aprobados por el Comité de Compensación bajo el Plan de Incentivos de Inicio de Empleo 2024 de la compañía. Las RSUs se consolidarán en un plazo de cuatro años, con una cuarta parte consolidándose anualmente en el aniversario de la fecha de concesión. Sarepta, líder en medicina genética de precisión para enfermedades raras, mantiene posiciones de liderazgo en la distrofia muscular de Duchenne y las distrofias musculares de cintura, con más de 40 programas en desarrollo.
사렙타 테라퓨틱스 (NASDAQ:SRPT)는 2024년 10월에 채용된 15명의 신입 직원에게 주식 보상을 부여했습니다. 이 보상은 12,165개의 제한된 주식 단위(RSU)로 구성되며, 회사의 2024년 취업 시작 인센티브 계획에 따라 보상위원회에서 승인되었습니다. RSU는 4년 동안 분할 지급되며, 매년 부여일 기념일에 1/4이 지급됩니다. 사렙타는 희귀 질병에 대한 정밀 유전자 의학의 선두주자로, 듀셰네 근이영양증과 사지띠 근이영양증에서 리더십을 유지하며 40개 이상의 개발 프로그램을 보유하고 있습니다.
Sarepta Therapeutics (NASDAQ:SRPT) a accordé des récompenses en actions à 15 nouveaux employés recrutés en octobre 2024. Les récompenses, qui se composent de 12 165 unités d'actions restreintes (RSU), ont été approuvées par le Comité de rémunération dans le cadre du Plan d'incitation à l'embauche 2024 de la société. Les RSU acquériront des droits sur quatre ans, avec un quart acquérant des droits chaque année à l'anniversaire de la date d'attribution. Sarepta, un leader dans la médecine génétique de précision pour les maladies rares, maintient des positions de leader dans la dystrophie musculaire de Duchenne et les dystrophies musculaires de ceinture, avec plus de 40 programmes en développement.
Sarepta Therapeutics (NASDAQ:SRPT) hat 15 neuen Mitarbeitern, die im Oktober 2024 eingestellt wurden, Aktienvergütungen gewährt. Diese Vergütungen bestehen aus 12.165 beschränkten Aktieneinheiten (RSUs) und wurden vom Vergütungsausschuss gemäß dem Beschäftigungsbeginn-Incentive-Plan 2024 des Unternehmens genehmigt. Die RSUs werden über vier Jahre übertragen, wobei ein Viertel jährlich am Jahrestag des Gewährungstags übertragen wird. Sarepta, ein führendes Unternehmen in der präzisen Gentherapie für seltene Krankheiten, hält führende Positionen in der Duchenne-Muskeldystrophie und den Gürtelmuskeldystrophien, mit über 40 Entwicklungsprogrammen.
- None.
- None.
The employees received in the aggregate 12,165 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031524581/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many RSUs did Sarepta Therapeutics (SRPT) grant to new employees in October 2024?
What is the vesting schedule for Sarepta Therapeutics' (SRPT) October 2024 RSU grants?
How many development programs does Sarepta Therapeutics (SRPT) currently have?
